Developing the Life Sciences Business
First written in FY2016. 9 of 25 entries say "Restated". Latest entry: 2026-08-07.
0 other companies' latest entry also says "Cited as achieved".
- FY2026AdvancedAnnual report
「In biomedical, the Company aims to achieve profitability at an early stage by deepening its presence in China, where the medical collagen and gelatin market is expanding. It is also focusing on the early commercialization of collagen microfibers, a medium- to long-term growth driver.」
For the biomedical business, the Company explicitly stated its policy of achieving early profitability by deepening its presence in the Chinese market, while also commercializing collagen microfibers at an early stage as a medium- to long-term growth driver. - FY2026-H1AdvancedAnnual report
「(Biomedical) Although domestic sales declined due to lower production volumes at major customers in Japan, sales to overseas markets increased, resulting in total biomedical revenue of ¥183 million, up 11.6% year on year.」
Although sales declined due to lower production volumes at major domestic customers, growth in overseas sales resulted in total biomedical revenue of ¥183 million, up 11.6% year on year. - FY2025AdvancedAnnual report
「In the biomedical business, we aim to achieve profitability early by deepening our presence in China, where the medical collagen and gelatin market is expanding.」
For the life sciences and biomedical businesses, the Company gave concrete form to its policy of achieving early profitability by deepening its presence in the Chinese market. In terms of results, biomedical revenue was ¥349 million, up 31.8% year on year. - FY2025-H1RaisedAnnual report
「1. Fundamental enhancement of earnings capability through stronger cost competitiveness from restructuring the production system and turning the biomedical business profitable」
The Company explicitly stated its aim of turning the biomedical business profitable in the medium-term management plan covering the fiscal years ending March 2025 through March 2027, shifting from its previous policy of developing the biomedical and life sciences businesses. - FY2023-Q3AdvancedAnnual report
「In December 2022, the Company completed Mirai-kan, a new research, development and manufacturing building, consolidating the research and development and production functions for biomedical products and the research and development functions of all business divisions to create products leading to new businesses.」
Mirai-kan, the new research, development and manufacturing building consolidating biomedical product production and the research and development functions of all business divisions, was completed in December 2022, moving the project from the construction stage toward operation. - FY2022-Q3AdvancedAnnual report
「Sales of medical collagen and gelatin increased, driven by new sales expansion initiatives for medical devices.」
The Company reported increased revenue from medical collagen and gelatin as a result of new sales expansion initiatives for medical devices. - FY2022-Q2AdvancedAnnual report
「In September 2021, construction began on Mirai-kan, a new research building intended to strengthen the business base by consolidating biomedical product production and the research and development functions of all business divisions and creating products leading to new businesses. Completion was scheduled for autumn 2022.」
For Mirai-kan, the new research building for developing the biomedical business, construction began in September 2021, moving the project to the stage with completion scheduled for autumn 2022. - FY2021AdvancedAnnual report
「The Company will consolidate the production and research and development functions for biomedical products and construct a new research building, Mirai-kan, at its Osaka Plant. Once operational, the new building will enhance the competitiveness of medical collagen and gelatin in terms of quality, cost and production volume, and expand sales.」
The policy of developing life sciences and biomedical as future businesses moved into a concrete execution phase, with the consolidation of production and research and development functions and the construction of a new research building. - FY2020-Q2RestatedAnnual report
「The Group's management policies under the medium-term management plan ending in the fiscal year ending March 2021 are as follows. 1. The 3 core areas are food solutions, health support and biomedical.」
The Company continues the policy of making the 3 core areas, including biomedical, a management priority under the medium-term management plan ending in the fiscal year ending March 2021. - FY2020-Q1RestatedAnnual report
「The Group's management policies under the medium-term management plan ending in the fiscal year ending March 2021 are as follows. 1. The 3 core areas are food solutions, health support and biomedical.」
Under the medium-term management plan ending in the fiscal year ending March 2021, the Company continues its policy of placing the 3 core areas, including biomedical, at the center of management. - FY2019-Q3RestatedAnnual report
「1. The 3 core areas are food solutions, health support and biomedical.」
The Company continues its policy of placing the 3 core areas, including biomedical, at the center of its new medium-term management plan. - FY2019-Q2RestatedAnnual report
「1. The 3 core areas are food solutions, health support and biomedical.」
Under the new 3-year medium-term management plan, the Company continues its policy of placing the 3 core areas, including biomedical, at the center of management. - FY2019-Q1RestatedAnnual report
「1. The 3 core areas are food solutions, health support and biomedical.」
The Company continues to position the 3 core areas, including biomedical, at the center of its new medium-term management plan. - FY2018RestatedAnnual report
「The Company will promote the life sciences business by developing medical materials that are safe for use in the body, while also promoting awareness in the pharmaceutical and regenerative medicine fields, with the aim of expanding the business.」
The Company continues to advance research and development of medical materials, awareness-building activities in the pharmaceutical and regenerative medicine fields, and business expansion. - FY2018-Q3RestatedAnnual report
「Under this corporate vision, the group worked to provide products that create new value, pursue research and development in the health and beauty and regenerative medicine fields, explore new manufacturing methods, and strengthen competitiveness through optimised production and sales.」
Research and development in the health, beauty and regenerative medicine fields is continuing. - FY2018-Q2RestatedAnnual report
「Under this corporate vision, the group actively promoted proposals for high-value-added products that address customer needs and worked to raise awareness, including by holding the Life Science Biomaterials Study Group for the second consecutive year.」
The Company held the Life Sciences Biomaterials Study Group for the second consecutive year and is working to raise awareness of the life sciences field. - FY2018-Q1RestatedAnnual report
「Under this corporate vision, the group worked to strengthen competitiveness through cost reductions such as production efficiency improvements and through optimised production and sales, provide products that create new value, and pursue research and development in the health and beauty and regenerative medicine fields.」
Research and development in the health, beauty and regenerative medicine fields has continued. - FY2017RaisedAnnual report
「The Company will promote the adoption of life sciences products in the field of regenerative medicine based on research and development of materials for research and medical use, and develop the business into a core business.」
The positioning of the objective became more ambitious, shifting from developing life sciences as a conventional “new source of revenue” to promoting its adoption in regenerative medicine and developing it into a “core business.” - FY2016First statedAnnual report
「The Company will actively develop its life sciences business as a new future source of revenue for the Group. Leveraging its production technology for medical gelatin and collagen with a high level of safety, it will provide high-value-added materials for product development by iPS cell-related industries and medical device manufacturers, and develop the business as a new business.」
The Company will develop medical gelatin and collagen as a new source of revenue for iPS cell-related industries and medical device manufacturers.